News | February 25, 2009

Some Cath Lab Directors Say CVIS Deliver Limited Financial Benefits, Satisfaction

February 23, 2009 - Cardiovascular information systems (CVIS) are not delivering quantifiable financial benefits, according to cardiac cath lab directors who participated in an independent national survey completed in January on behalf of Wolters Kluwer Health and ProVation Medical.

The survey of hospital cardiac cath lab directors was designed to measure the use and satisfaction levels with CVIS and procedure documentation systems.

Thirty one percent of cardiac cath lab directors reported no quantifiable improvements in revenues or the revenue cycle since implementing CVIS, due in part to continued reliance on dictation for physician documentation. Overall, 69 percent of respondents reported that physicians continue to dictate, despite clinical procedure documentation for physicians being identified by 51 percent of cardiology directors as an “extremely important” CVIS feature.

Four in 10 cardiac cath lab directors whose physicians dictate felt that documentation issues have at least a “moderate” impact on revenues. One-fourth also estimated that they could realize an annual savings of $100,000 or more by eliminating the costs associated with dictation and transcription.

“When properly designed and implemented, technological systems for cardiology should streamline workflow, reduce costs and increase revenue,” said Arvind Subramanian, president and CEO of Wolters Kluwer Health Clinical Solutions and ProVation Medical. “However, when they are difficult to use, don’t offer a solid return on investment (ROI) or do not integrate with other information systems, they cannot deliver the full scope of improvements health care organizations require to achieve their patient care and financial goals.”

This was borne out in the survey. The majority of respondents reported being only “somewhat satisfied” or “satisfied” with CVIS. Lower satisfaction rates were most closely associated with problems interfacing with other systems and hardware (10 percent); failure to function as promised (8 percent); not user-friendly (7 percent); poor vendor support (6 percent); and failure to offer a comprehensive array of features (5 percent).

Of the 31 percent who reported using software for procedure documentation, fewer than one in five said the application produced automatic CPT and ICD codes based on that documentation. As a result, 22 percent reported no quantifiable increase in revenues since implementing the documentation solution.

However, interest in clinical documentation software remains high. The majority (68 percent) of those whose physicians currently dictate said it was at least “somewhat likely” that they would implement physician procedure documentation within the next two years. Among the features identified as having the most influence over that purchasing decision were the ability to streamline workflows and increase efficiencies (88 percent), ease-of-use (86 percent) and physician satisfaction rates (72 percent).

By eliminating transcription and automating the documentation and coding processes, software can help deliver a solid ROI through reduced costs and improved reimbursement levels, the company said.

Renaissance Research, of Edwardsville, IL, conducted the national online survey Jan. 13-25, 2009. The survey was completed by 151 hospital cardiology and cardiac lab directors, providing a margin of error of +/- 8 percentage points.

ProVation MD software helps in procedure documentation, coding compliance and replaces dictation/transcription. The company will be exhibiting its ProVation MD Cardiology software at the American College of Cardiology’s 58th Annual Scientific Session in March 29–31, in Orlando.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init